BioBlast Pharma (ORPN) Posts Q2 Loss of 26c/Share

BioBlast Pharma (NASDAQ: ORPN) reported Q2 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28).

Colin Foster, President & CEO, said, "During the second quarter we made significant progress in advancing our clinical and regulatory activities in the USA, Canada, and Israel across our pipeline of drug candidates. Of note, recently the U.S. Food and Drug Administration (FDA) granted Fast Track Designation and clearance to proceed with an Investigational New Drug Application (IND) for the development of Cabaletta to treat patients with oculopharyngeal muscular dystrophy (OPMD). Additionally, we have been granted an orphan drug designation from the European Commission for Cabaletta for the treatment of OPMD and Spinocerebellar Ataxia (SCA). Both of these events will help to expedite the continued development of our lead drug candidate in the United States and Europe. Moreover, we have announced positive preclinical in-vitro and in-vivo proof-of-concept study results of our novel read-through drug candidate (BBrm02) for Spinal Muscular Atrophy (SMA). This recent development will accelerate the BBrm2 platform into the clinical stage."

For earnings history and earnings-related data on BioBlast Pharma (ORPN) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
• UBS Reiterates Buy Rating on Dutch Bros Inc. (BROS): 'One of Strongest Growth Stories in Restaurants'